857 related articles for article (PubMed ID: 17973844)
21. Spectrum of Von Willebrand disease and inherited platelet function disorders amongst Indian bleeders.
Gupta PK; Charan VD; Saxena R
Ann Hematol; 2007 Jun; 86(6):403-7. PubMed ID: 17375300
[TBL] [Abstract][Full Text] [Related]
22. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3.
Berntorp E
Semin Thromb Hemost; 2006 Sep; 32(6):621-5. PubMed ID: 16977572
[TBL] [Abstract][Full Text] [Related]
23. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
Nichols WL; Hultin MB; James AH; Manco-Johnson MJ; Montgomery RR; Ortel TL; Rick ME; Sadler JE; Weinstein M; Yawn BP
Haemophilia; 2008 Mar; 14(2):171-232. PubMed ID: 18315614
[TBL] [Abstract][Full Text] [Related]
24. [Von Willebrand's disease in the IX Region of Chile].
Cabrera ME; Artigas CG; Páez E; Monsalve V; Zolezzi P; Arauco G; Espinoza R; Hevia C; Villegas J
Rev Med Chil; 1989 Apr; 117(4):423-30. PubMed ID: 2519397
[TBL] [Abstract][Full Text] [Related]
25. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
[TBL] [Abstract][Full Text] [Related]
26. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
[TBL] [Abstract][Full Text] [Related]
27. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
28. Differences between heterozygous dominant and recessive von Willebrand's disease type I expressed by bleeding symptoms and combinations of factor VIII variables.
Wahlberg TB; Blombäck M; Ruggeri ZM
Thromb Haemost; 1983 Dec; 50(4):864-8. PubMed ID: 6420925
[TBL] [Abstract][Full Text] [Related]
29. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
30. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
31. Concurrence of von Willebrand's disease and hemophilia A: implications for carrier detection and prevalence.
Miller CH; Hilgartner MW; Harris MB; Bussel JB; Aledort LM
Am J Med Genet; 1986 May; 24(1):83-94. PubMed ID: 3085499
[TBL] [Abstract][Full Text] [Related]
32. Emergency department care for patients with hemophilia and von Willebrand disease.
Singleton T; Kruse-Jarres R; Leissinger C
J Emerg Med; 2010 Aug; 39(2):158-65. PubMed ID: 18757163
[TBL] [Abstract][Full Text] [Related]
33. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
35. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
36. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
37. Treatment of von Willebrand's disease.
Mannucci PM
J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
[TBL] [Abstract][Full Text] [Related]
38. Correlation between circulating levels of von Willebrand's antigen II and von Willebrand factor: discrimination between type I and type II von Willebrand's disease.
McCarroll DR; Ruggeri ZM; Montgomery RR
J Lab Clin Med; 1984 May; 103(5):704-11. PubMed ID: 6609219
[TBL] [Abstract][Full Text] [Related]
39. Factor VIII-von Willebrand factor binding defects in autosomal recessive von Willebrand disease type Normandy and in mild hemophilia A. New insights into factor VIII-von Willebrand factor interactions.
Jacquemin M
Acta Haematol; 2009; 121(2-3):102-5. PubMed ID: 19506355
[TBL] [Abstract][Full Text] [Related]
40. von Willebrand disease: laboratory aspects of diagnosis and treatment.
Favaloro EJ; Lillicrap D; Lazzari MA; Cattaneo M; Mazurier C; Woods A; Meschengieser S; Blanco A; Kempfer AC; Hubbard A; Chang A
Haemophilia; 2004 Oct; 10 Suppl 4():164-8. PubMed ID: 15479392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
